Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...
With the Nike Mind 001 and 002, Nike is now in the neuroscience game. Its first foray into “mind altering” footwear comes by way of a pair of mules (the Mind 001) and a matching sneaker (the Mind 002) ...
Nike continues to redefine the intersection of wellness and performance with the official look at the Nike Mind 002 in “Light Violet Ore.” Designed for those who prioritize mental clarity as much as ...
This humanized IgG1 antibody inhibits an immune checkpoint protein called programmed death ligand, aka PD-L1, stimulating the immune system. Checkpoint inhibitors, including other antibodies, are ...
In an exclusive interview with Hypebeast, the designer shares how she turned her hand to transforming her favorite rum bottle.
The Thor 002 uses a 256 x 192 thermal sensor – its true resolution – and produces a digitally enhanced 512 x 384 image to make thermal maps crisper. Sure, this isn't high-end imaging tech, which you'd ...
The Manifest 002 ownership team Susan Morgan, Brian Merrit, K.J. Hughes and Chef Erik Bruner-Yang. The barbershop, men’s clothing boutique, and restaurant opened in the Union Market area in late ...
After all, this lofty third space offers a barbershop, coffee shop, clothing store, restaurant, cocktail lounge, and private dining space, all of it accessed through a minty green entry floor designed ...
While Takomo is now firmly established as one of the most disruptive equipment manufacturers to emerge this generation, the Finnish brand's offering outside of its irons tends to fly a little under ...
Primary Endpoint met: Statistically significant reduction in blood-fat levels after eating (-51.9%) Multiple secondary endpoints met: Including statistically significant reduction in weight regain ...
An expert summarizes that TARA-002, a novel immunotherapy derived from Streptococcus pyogenes, is showing promising results in a phase 2 trial for non–muscle-invasive bladder cancer—particularly in ...